Notice of Preliminary Results
Oxford, UK – 27 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, will announce its preliminary results for the year ended 31 December 2014 on Thursday 26 February 2015.
A presentation for analysts will take place at the offices of Peel Hunt, Moor House, 120 London Wall, London, EC2Y 5ET at 9.30am. A webcast of the presentation will be available on the Company’s website.
For further information please contact:
+44 (0) 20 3727 1097
Circassia is a specialty biopharmaceutical company focused on the development and commercialisation of a range of allergy immunotherapy product candidates. Established in 2006, the Company has used its proprietary ToleroMune® technology to develop a new class of therapies, the Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs), which have the potential to revolutionise allergy treatment.
The Company’s portfolio of SPIREs is designed to treat a broad range of seasonal and perennial allergies. The most advanced, Cat-SPIRE, targets cat allergy and is currently in phase III development. Three other product candidates, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies.
As Circassia continues to grow, the Company remains focused on its founding principle – a commitment to improving patients’ lives by controlling immune responses. Further information is available at: www.circassia.com.